Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795999 | 1.00 | PRCP (1.00) | PRCPGAAMEN1OPRM1SLC22A1 | |
| SCHEMBL29768302 | 1.00 | PRCP (1.00) | PRCPGAAMEN1OPRM1SLC22A1 | |
| SCHEMBL2793867 | 1.00 | PRCP (1.00) | PRCPGAAMEN1OPRM1SLC22A1 | |
| Hydrochloric Acid SCHEMBL2790424 | 0.98 | PRCP (0.97) | PRCPGAAMEN1OPRM1SLC22A1 | |
| SCHEMBL3865487 | 0.98 | PRCP (0.97) | PRCPGAAMEN1OPRM1SLC22A1 | |
| SCHEMBL28083503 | 0.95 | PRCP (0.90) | PRCPGAAMEN1OPRM1SLC22A1 | |
| SCHEMBL1738261 | 0.91 | PRCP (0.83) | PRCPGAAMEN1SLC22A1RECQL | |
| SCHEMBL2796275 | 0.83 | PRCP (0.71) | PRCPGAAMEN1OPRM1SLC22A1 | |
| SCHEMBL30032724 | 0.83 | PRCP (0.71) | PRCPGAAMEN1OPRM1SLC22A1 | |
| SCHEMBL2796276 | 0.83 | PRCP (0.71) | PRCPGAAMEN1OPRM1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114671807-A | Preparation method of 1-substituted isoquinoline compound | 联化科技（德州）有限公司 | 2022-06-28 | — | — | CN | disclosed |
| EP-2149560-B1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-13 | — | — | EP | disclosed |
| EP-2149560-B1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2015-05-13 | — | — | EP | disclosed |
| US-20150073165-A1 | CATALYST COMPOUNDS | THE UNIVIERSITY OF LIVERPOOL (GB) | 2015-03-12 | — | — | US | disclosed |
| US-20150073165-A1 | CATALYST COMPOUNDS | THE UNIVIERSITY OF LIVERPOOL (GB) | 2015-03-12 | — | — | US | disclosed |
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-09-01 | — | — | US | disclosed |
| US-7985753-B2 | Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators | MERZ PHARMA GMBH & CO. KGAA (DE) | 2011-07-26 | — | — | US | disclosed |
| EP-2295439-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | Merz Pharma GmbH & Co. KGaA (DE) | 2011-03-16 | — | — | EP | disclosed |
| EP-2054416-B1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO KGAA (DE) | 2011-01-05 | — | — | EP | disclosed |
| EP-2054416-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | Merz Pharma GmbH & Co. KGaA (DE) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008069632-A1 | 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES HAVING EFFECTS OF PREVENTING AND TREATING DEGENERATIVE AND INFLAMMATORY DISEASES | UNIVERSITY OF ULSAN FOUNDATION FOR INDUSTRY COOPERATION (KR) | 2008-06-12 | — | — | WO | disclosed |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008015269-A1 | SUBSTITUTED PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2008-02-07 | — | — | WO | disclosed |
| EP-0801067-B1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 2003-03-05 | — | — | EP | disclosed |
| US-6174896-B1 | MUSCARINIC RECEPTOR ANTAGONISTIC ACTIVITY; FOR THERAPY AND PROPHYLAXIS FOR UROLOGIC DISEASES, RESPIRATORY DISEASES OR DIGESTIVE DISEASES | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-16 | — | — | US | disclosed |
| US-6017927-A | Quinuclidine derivatives and medicinal composition thereof | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-01-25 | — | — | US | disclosed |
| CN-1045601-C | Novel quinuclidine derivatives and medicinal composition thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1999-10-13 | — | — | CN | disclosed |
| CN-1171109-A | Novel quinuclidine derivatives and medicinal composition thereof | YAMANOUCHI PHARMA CO LTD (JP) | 1998-01-21 | — | — | CN | disclosed |
| EP-0801067-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1997-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212956-A1 | Pyrazolopyrimidines for treating CNS disorders | GRM5, GRM3, GRM1 | PRCP 2270/4885GAA 4755/4885MEN1 2974/4885 |
| US-20150073165-A1 | CATALYST COMPOUNDS | NQO1, IDH2, IDH3B | PRCP 3752/4885GAA 3286/4885MEN1 262/4885 |
| US-20080039458-A1 | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | GRM5, GRM1, GRM3 | PRCP 2427/4885GAA 4741/4885MEN1 3197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.